BCRX EBITDA Growth
Biocryst Pharmaceuticals Inc · EBITDA Growth
BCRX EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-577.55%period ending
BCRX TTM EBITDA YoY % (-31.25% → -577.55%)
Year-over-year change
High-resolution chart · PNG
BCRX ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -577.5532% | |
| -884.2519% | |
| 2,642.8326% | |
| 447.8043% | |
| 244.6365% | |
| 146.8085% | |
| 111.0096% | |
| 80.3608% | |
| 66.4081% | |
| 14.5235% | |
| 19.1298% | |
| -28.1492% | |
| -4.9252% | |
| 1.1197% | |
| -18.1669% | |
| 46.7284% | |
| 30.136% | |
| 34.6631% | |
| 27.2133% | |
| -60.7405% | |
| -72.0026% | |
| -79.6951% | |
| -73.7134% | |
| 8.0919% | |
| 9.5115% | |
| -6.6345% | |
| -5.4487% | |
| -45.6073% | |
| -64.9576% | |
| -41.439% | |
| -61.5664% | |
| -101.0822% | |
| -79.4748% | |
| -75.0657% | |
| -23.2294% | |
| 31.4784% | |
| 39.5638% | |
| 11.3978% | |
| -18.8052% | |
| -90.28% | |
| -144.0756% | |
| 2.6192% | |
| 3.5313% | |
| 5.7145% | |
| 21.1002% | |
| -46.2444% | |
| -59.1583% | |
| -19.611% | |
| -13.3588% | |
| -4.8301% | |
| 18.4581% | |
| 67.6907% | |
| 68.2461% | |
| 69.2268% | |
| 69.7378% | |
| -86.0168% | |
| -104.5134% | |
| -132.3758% | |
| -217.4979% | |
| -529.8511% | |
| -536.1843% | |
| -647.8585% | |
| -164.6608% | |
| 56.9129% | |
| 56.2284% | |
| 73.7169% | |
| 52.524% | |
| 55.1003% | |
| 60.5179% | |
| 41.0029% | |
| -13.7925% | |
| -28.113% | |
| -17.7572% | |
| 7.6464% | |
| 51.3782% | |
| 29.7859% | |
| -1.4473% | |
| -30.8804% | |
| -75.4262% | |
| -73.624% | |
| -54.554% | |
| -36.1415% | |
| -23.5816% | |
| -32.9323% | |
| -34.3494% | |
| -48.1321% | |
| -83.5783% | |
| -68.7051% | |
| -50.7177% | |
| -12.3023% | |
| 26.4467% | |
| 29.5251% | |
| 11.4332% | |
| -79.9111% | |
| -276.7709% | |
| -125.1011% | |
| -39.3138% | |
| 37.3522% | |
| 63.2624% | |
| 19.3946% |